

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**WUXI APPTEC CO., LTD.\***  
**無錫藥明康德新藥開發股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*  
**(Stock Code: 2359)**

**VOLUNTARY ANNOUNCEMENT**

This announcement is made by WuXi AppTec Co., Ltd.\* (無錫藥明康德新藥開發股份有限公司) (the “**Company**” or “**WuXi AppTec**”) on a voluntary basis.

Reference is made to the announcements of the Company dated January 26, 2024 and January 29, 2024 (collectively, the “**Announcements**”), in relation to, among other things, WuXi AppTec being named in certain proposed legislation (the “**Draft Legislation**”) that was recently introduced to the U.S. House of Representatives and the U.S. Senate. Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcements.

The Company has noted the recent fluctuations in price and trading volume of the Company's shares. The Board confirms that the production and operational activities of the Company remain normal, and there are no material changes to the daily operations of the Company.

As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the pharmaceutical and healthcare industry around the world. We do not have a human genomics business and we do not collect human genomic data in our businesses. The Company is not affiliated with any government or armed force thereof. We strongly believe that WuXi AppTec **HAS NOT posed, DOES NOT pose and WILL NOT pose** a national security risk to any country, and therefore should not be preemptively designated as a “biotechnology company of concern” in the Draft Legislation. The Company will continue to work closely with our advisors to communicate with the relevant parties involved in the ongoing legislative process for the Draft Legislation, the contents of which remain subject to further review and changes.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board  
**WuXi AppTec Co., Ltd.\***  
**Dr. Ge Li**  
*Chairman*

Hong Kong, February 4, 2024

*As of the date of this announcement, the board of directors of the Company comprises Dr. Ge Li, Dr. Minzhang Chen, Mr. Edward Hu, Dr. Steve Qing Yang and Mr. Zhaohui Zhang as executive Directors, Mr. Xiaomeng Tong and Dr. Yibing Wu as non-executive Directors and Ms. Christine Shaohua Lu-Wong, Dr. Wei Yu, Dr. Xin Zhang, Ms. Zhiling Zhan and Mr. Dai Feng as independent non-executive Directors.*

\* *For identification purposes only*